Search Results - "Fiskus W"

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.

Authors: Fiskus, W Sharma, S Saha, S et al.

Source: Leukemia (08876924). Jun2015, Vol. 29 Issue 6, p1267-1278. 12p. 1 Diagram, 6 Graphs.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Authors: Fiskus, W Sharma, S Shah, B et al.

Source: Leukemia (08876924). Nov2014, Vol. 28 Issue 11, p2155-2164. 10p. 7 Graphs.

515 Superior Efficacy of Co-treatment with NPM1 Antagonist and FLT3 Inhibitor or Pan-histone Deacetylase Inhibitor Against Cultured and Primary Human AML Cells Co-expressing Mutant NPM1 and FLT3-ITD

Authors: Balusu, R. Huffman, N. Fiskus, W. et al.

Source: European Journal of Cancer. Nov2012 Supplement, Vol. 48, p159-159. 1p.

Treatment with Histone Deacetylase Inhibitors Creates 'BRCAness' and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin.

Authors: Bhalla, K. N. Rao, R. Sharma, P. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p2199-2200. 2p.

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.

Authors: Fiskus W Mill CP Piel J et al.

Source: HemaSphere [Hemasphere] 2026 Jan 15; Vol. 10 (1), pp. e70289. Date of Electronic Publication: 2026 Jan 15 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.

Authors: Fiskus W Mill CP Issa GC et al.

Source: Blood [Blood] 2026 Jun 04; Vol. 147 (23), pp. 2809-2820.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.

Authors: Birdwell CE Fiskus W Mill CP et al.

Source: Leukemia [Leukemia] 2026 Apr; Vol. 40 (4), pp. 856.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE; In Process

Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.

Authors: Fiskus W Mill CP Birdwell C et al.

Source: Blood cancer journal [Blood Cancer J] 2025 May 21; Vol. 15 (1), pp. 99. Date of Electronic Publication: 2025 May 21.

Publication Type: Published Erratum

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; PubMed not MEDLINE

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.

Authors: Birdwell CE Fiskus W Mill CP et al.

Source: Leukemia [Leukemia] 2026 Feb; Vol. 40 (2), pp. 304-313. Date of Electronic Publication: 2025 Dec 19.

Publication Type: Journal Article; Research Support, N.I.H., Intramural

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Authors: Fiskus W Mill CP Piel J et al.

Source: Blood cancer journal [Blood Cancer J] 2025 Mar 15; Vol. 15 (1), pp. 40. Date of Electronic Publication: 2025 Mar 15.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.

Authors: Fiskus W Masarova L Mill CP et al.

Source: Blood advances [Blood Adv] 2025 Nov 11; Vol. 9 (21), pp. 5598-5609.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.

Authors: DiNardo CD Jen WY Montalban-Bravo G et al.

Source: Blood neoplasia [Blood Neoplasia] 2025 Jul 25; Vol. 2 (4), pp. 100145. Date of Electronic Publication: 2025 Jul 25 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Elsevier, Inc Country of Publication: United States NLM ID: 9918841988906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2950-3280 (Electronic) Linking ISSN: 29503280 NLM ISO Abbreviation: Blood Neoplasia Subsets: PubMed not MEDLINE

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Authors: Wang Z Skwarska A Poigaialwar G et al.

Source: Blood [Blood] 2025 Jul 17; Vol. 146 (3), pp. 341-355.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.

Authors: Bataller A Loghavi S Gerstein Y et al.

Source: American journal of hematology [Am J Hematol] 2023 Nov; Vol. 98 (11), pp. 1780-1790. Date of Electronic Publication: 2023 Sep 04.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.

Authors: El Hussein S Medeiros LJ Gruschkus SK et al.

Source: Virchows Archiv : an international journal of pathology [Virchows Arch] 2023 Jun; Vol. 482 (6), pp. 1011-1019. Date of Electronic Publication: 2023 Mar 03.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.

Authors: Fiskus W Mill CP Birdwell C et al.

Source: Blood cancer journal [Blood Cancer J] 2023 Apr 13; Vol. 13 (1), pp. 53. Date of Electronic Publication: 2023 Apr 13.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.

Authors: Fiskus W Mill CP Bose P et al.

Source: Blood [Blood] 2025 Feb 06; Vol. 145 (6), pp. 612-624.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.

Authors: Cuglievan B Kantarjian H Rubnitz JE et al.

Source: Leukemia [Leukemia] 2024 Oct; Vol. 38 (10), pp. 2073-2084. Date of Electronic Publication: 2024 Aug 23.

Publication Type: Journal Article; Review

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.

Authors: Fiskus W Manshouri T Birdwell C et al.

Source: Blood cancer journal [Blood Cancer J] 2022 Jan 31; Vol. 12 (1), pp. 23. Date of Electronic Publication: 2022 Jan 31.

Publication Type: Letter

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).

Authors: Fiskus W Boettcher S Daver N et al.

Source: Blood cancer journal [Blood Cancer J] 2022 Jan 11; Vol. 12 (1), pp. 5. Date of Electronic Publication: 2022 Jan 11.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE